[EN] OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS D'ACIDE OXOACRIDINYLE ACÉTIQUE ET PROCÉDÉS D'UTILISATION
申请人:SILICON SWAT INC
公开号:WO2020232375A1
公开(公告)日:2020-11-19
Compounds of Formulae I, II, their pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formulae I or II as effective modulators of STING are also provided.
[EN] BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER<br/>[FR] COMPOSÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
申请人:SCORPION THERAPEUTICS INC
公开号:WO2022072634A1
公开(公告)日:2022-04-07
This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.
Oxoacridinyl acetic acid derivatives and methods of use
申请人:Silicon SWAT, Inc.
公开号:US10745358B2
公开(公告)日:2020-08-18
Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.
本研究提供了能够与干扰素基因刺激物(STING)蛋白结合并调节其活性的式 I 化合物或其药学上可接受的盐或酯。还提供了涉及式 I 化合物作为 STING 有效调节剂的方法。
OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE
申请人:Silicon SWAT, Inc.
公开号:US20190161449A1
公开(公告)日:2019-05-30
Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.